Compare Oracle Corporation (ORCL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs GeneDx Holdings Corp — how do they compare? Oracle Corporation trades at $141.53 (market cap $411.34B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Oracle Corporation is far larger — about 203.6× GeneDx Holdings Corp's market cap, and Oracle Corporation pays a 1.47% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oracle Corporation for 72 Days and GeneDx Holdings Corp for 19 Days on average.
| ORCL | WGS | |
|---|---|---|
Market Cap | $411.34B | $2.02B |
Volume | 41,276,815 | 734,640 |
Sector | Technology | Health |
52-Week High | $313.00 | $167.51 |
52-Week Low | $114.99 | $34.51 |
Typical Hold Time | 72 Days | 19 Days |
Enterprise Value | $535.15B | $2.05B |
Dividend Yield | 1.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle Corporation (ORCL) is trading at $135.56, down 5.58% amid broader market volatility despite strong Q1 2026 earnings that beat expectations with EPS of $2.11 versus $1.96. The stock faces technical bearish signals with support at $133 and resistance at $141, while fundamentals show robust revenue growth to $57.4B in 2025 and net income margin expansion to 26.36%. Recent AI-driven infrastructure investments and layoffs highlight strategic shifts to capitalize on cloud demand.
Oracle's outlook remains positive with analyst consensus price target of $236.52 implying 74% upside, supported by 65% buy ratings. Key opportunities include AI cloud revenue growth accelerating 120% in Q1 2026, though risks persist from high debt levels ($85.3B long-term) and sensitivity to Fed policy given the stock's 1.9 beta. Investors should weigh strong profitability against execution risks in aggressive data center expansion.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
